Back to search results

Pancreas Registry for High-Risk Individuals and Pancreatic Diseases

This is an observational study creating a registry of people with pancreatic diseases or those at high risk for pancreatic cancer. It aims to collect information on individuals with conditions like pancreatic cancer, pancreatitis (inflammation of the pancreas), pancreatic cysts, or a family history of pancreatic cancer. You might be able to join if you have a close relative with pancreatic cancer, or if you carry certain genetic mutations (like BRCA1, BRCA2, PALB2, ATM, CDKN2A, STK11) and have a family history of pancreatic cancer. The study is looking to enroll 1368 participants and will track the number of individuals with pancreatic diseases over 10 years to better understand how these conditions develop.

Study design
This is an observational study, meaning it collects information without testing a specific intervention. It aims to enroll 1368 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 10 years to observe the number of individuals with pancreatic diseases.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02775461

Pancreas Registry and High Risk Registry

Recruiting
Not specifiedAges 18+Observational
Icahn School of Medicine at Mount Sinai
~1,368 participants
Updated 2026-02-11 on ClinicalTrials.gov

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of individuals with pancreatic diseases
Measured over 10 years

Conditions

Pancreas Cancer
Pancreatitis
Chronic Pancreatitis
Pancreatic Cyst
Family History of Pancreas Cancer
Genetic Mutations

Explore related trials

Chronic PancreatitisFamilial Atypical Multiple Mole-MelanomaHereditary PancreatitisLynch SyndromePancreatic CarcinomaPancreatic CystPeutz-Jeghers SyndromeATM GeneBRCA1 GeneBRCA2 GeneCDKN2A GeneLynch SyndromePartner and Localizer of BRCA2STK11 Gene

Where it's being run

2 sites across 1 states
New York2

Study leadership

  • Aimee Lucas, MD, MS · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

Joyce Serebrenik
[email protected]
(212) 241-7269
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

At least 1 first degree relative affected with Pancreatic Cancer
Any of (BRCA1, BRCA2, PALB2, ATM) mutations + 1 family member with Pancreatic Cancer
mFAMMM (p16,CDKN2A mutations) + 1 family member with Pancreatic cancer
Known mutation carrier for STK11 (Peutz Jeghers Syndrome)
Lynch syndrome (HNPCC) + 1 family PDAC
Known mutation carrier for Hereditary pancreatitis
Individuals with a history of pancreatic cyst(s) (IPMN's) that measure ≥ 1 cm

Exclusion

Patients who do not speak English or Spanish
Refusal by patient
Individuals under the age of 18 years

What this trial measures

  • Number of individuals with pancreatic diseases10 years

    Number of individuals and their family members who have pancreatic diseases and may be at increased risk of developing pancreatic cancer over normal population risk.